RxDoctor Payments Data

Adam Greene, MD

Cardiovascular Disease · Anderson, INNPI 1083680763

Payments from drug & device makers

$987in general payments, 2019–2025

Across 56 payments — averaging $17.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$310
  • AstraZeneca$113
  • Sanofi-aventis U.S. LLC$88
  • Amarin Pharma, Inc.$60
  • Astellas Pharma US Inc$58
  • Johnson & Johnson$55
  • plus $302 from 12 others

What the payments were for

  • Food & beverage$97499%
  • Education$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$987 in reported general payments places this provider in the 30th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$70,819
Medicare patients
1,012
Services billed
1,919

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban505$652,655
EntrestoSacubitril/Valsartan113$159,490
JardianceEmpagliflozin46$71,690
XareltoRivaroxaban43$53,943
Repatha SureclickEvolocumab39$37,134
Praluent PenAlirocumab18$25,334
MultaqDronedarone Hcl16$18,050
FarxigaDapagliflozin Propanediol11$13,264
VascepaIcosapent Ethyl25$13,263
Metoprolol Succinate682$10,419
Ranolazine ErRanolazine60$9,143
Icosapent Ethyl14$5,644
Atorvastatin Calcium405$4,979
Diltiazem 24hr Er (Cd)Diltiazem Hcl167$4,965
Valsartan157$4,528

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$29$652,655505 claims
NovartisEntresto$310$159,490113 claims
Boehringer IngelheimJardiance$12$71,69046 claims
Johnson & JohnsonXarelto$55$53,94343 claims
Sanofi-aventis U.S. LLCMultaq$88$18,05016 claims
AstraZenecaFarxiga$113$13,26411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Anderson

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →